Health economic evaluation in nasopharyngeal carcinoma: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

WENG Junling ^1,2 , LUO Bingxing ^1,2 , XIAO Dunming ^1,2 ,  CHEN Yingyao ^1,2

1. School of Public Health, Fudan University, Shanghai 200032, P. R. China;
2. National Health Commission Key Laboratory of Health Technology Assessment (Fudan University), Shanghai 200032, P. R. China;

Corresponding?author：

CHEN Yingyao, Email: yychen@shmu.edu.cn

Keywords：

Nasopharyngeal carcinoma; Health economic evaluation; Systematic review

DOI：

10.7507/1672-2531.202301057

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the health economic evaluation of nasopharyngeal carcinoma (NPC). Methods The PubMed, Web of Science, EMbase, CNKI, WanFang Data and CBM databases were electronically searched to collect the health economic evaluations on NPC from inception to December 18, 2022. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies. A descriptive analysis was performed. Results A total of 20 studies were included, which contained 14 about different drug combinations, 6 about chemotherapy and the comparison among intensity modulated radiotherapy, conventional radiotherapy and surgery. The results showed that for patients with recurrent, metastatic, or advanced NPC, compared with docetaxel plus cisplatin, fluorouracil plus cisplatin or docetaxel and cisplatin plus fluorouracil, gemcitabine plus cisplatin (GP) was the most economical, and compared with GP or camrelizumab plus GP, toripalimab plus GP (TGP) was more economical. For early-stage NPC, intensity modulated radiotherapy was not economical compared with conventional radiotherapy and surgery. Conclusion Current evidence shows that GP and TGP are economical and can be popularized clinically.

Citation： WENG Junling, LUO Bingxing, XIAO Dunming, CHEN Yingyao. Health economic evaluation in nasopharyngeal carcinoma: a systematic review. Chinese Journal of Evidence-Based Medicine, 2023, 23(5): 555-560. doi: 10.7507/1672-2531.202301057 Copy

1.	Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet, 2019, 394(10192): 64-80.
2.	倪良平, 劉影. DCE-MRI與DWI對鼻咽癌臨床分期診斷價值的比較研究. 臨床放射學雜志, 2016, 35(4): 518-522.
3.	丘敏敏. 放療中T形口腔固定器的應用及食管癌肺受量預測模型的研究. 廣州: 南方醫科大學, 2021.
4.	牟文軒, 江慶華. 鼻咽癌患者經濟毒性研究進展. 廣西醫學, 2022, 44(6): 657-661.
5.	Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force. Value Health, 2022, 25(1): 10-31.
6.	洪明晃, 麥海強, 羅東華. N_(2-3)鼻咽癌患者輔助化療的成本效果分析. 中國腫瘤, 2000, (12): 21-22.
7.	王仁生, 韋波, 蘇莉, 等. 鼻咽癌兩種放射治療方案的成本效果分析. 中華腫瘤防治雜志, 2011, 18(9): 707-709.
8.	區通源, 潘智靈. 鼻咽癌藥物療法的藥效分析. 西北藥學雜志, 2013, 28(1): 82-84.
9.	鄧勛, 劉海燕, 王艷, 等. 康艾注射液輔助治療鼻咽癌的臨床用藥評價. 實用藥物與臨床, 2014, 17(5): 547-550.
10.	楊珍珍. 甘氨雙唑鈉用于食管癌和鼻咽癌放療增敏的Meta分析及藥物經濟學評價. 石家莊: 河北醫科大學, 2019.
11.	劉友平, 呂星, 鄒雄, 等. 單純微創手術與調強放射治療原發性Ⅰ期鼻咽癌的療效比較. 癌癥, 2020, 39(5): 201-212.
12.	彭迎春. GP與DP治療晚期轉移性鼻咽癌療效及成本效果分析. 吉首: 吉首大學, 2020.
13.	邱英鵬, 孫潭霖, 趙羽西, 等. 螺旋斷層放射治療系統的成本效果分析. 中國醫學裝備, 2020, 17(12): 1-4.
14.	歐陽麗輝, 張順芝, 何鴿飛, 等. 吉西他濱或氟尿嘧啶聯合順鉑治療晚期鼻咽癌的藥物經濟學評價. 醫藥導報, 2021, 40(2): 257-262.
15.	陳夢宇, 文衛平, 李健, 等. 內鏡手術治療復發性rT1-rT3期鼻咽癌基于馬爾可夫模型的成本-效果分析. 中華耳鼻咽喉頭頸外科雜志, 2022, 57(11): 1304-1310.
16.	Chen X, Liang W, Wan N, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol, 2019, 94: 80-85.
17.	Liao W, Huang J, Wu Q, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: a cost-effectiveness analysis. Oral Oncol, 2019, 93: 15-20.
18.	Fei Z, Xu T, Li M, et al. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol, 2020, 15(1): 230.
19.	Jin C, Zheng H, Zhan M, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol, 2020, 277(2): 577-584.
20.	Wu Q, Liao W, Huang J, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma. Oral Oncol, 2020, 103: 104588.
21.	Yang J, Han J, He J, et al. Real-world cost-effectiveness analysis of gemcitabine and cisplatin compared to docetaxel and cisplatin plus fluorouracil induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol, 2020, 10: 594756.
22.	She L, Tian K, Han J, et al. Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol, 2022, 12: 904372.
23.	Tian K, Han J, Wang Z, et al. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis. Oral Oncol, 2022, 128: 105842.
24.	Zhu Y, Liu K, Ding D, et al. Chemo-immunotherapy regimes for recurrent or metastatic nasopharyngeal carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol, 2022, 13: 858207.
25.	Li G, Xia YF, Huang YX, et al. Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: cost-effectiveness analysis. Head Neck, 2022, 44(2): 431-442.
26.	中國臨床腫瘤學會指南工作委員會. 鼻咽癌診療指南2022. 北京:人民衛生出版社, 2022, 27: 47, 63, 69.
27.	何朝光, 傅萬凱, 陳彩霞, 等. 1990和2017年中國鼻咽癌疾病負擔及其趨勢. 海峽預防醫學雜志, 2020, 26(4): 108-110.
28.	王木清, 江文霞, 張靜. 鼻咽癌門診病例的臨床特征及健康教育. 中國醫藥指南, 2015, 13(4): 17-19.
29.	黃志碧. 廣西惡性腫瘤經濟負擔的現狀、變動的趨勢及其影響因素的研究. 南寧: 廣西醫科大學, 2016.

1. Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet, 2019, 394(10192): 64-80.
2. 倪良平, 劉影. DCE-MRI與DWI對鼻咽癌臨床分期診斷價值的比較研究. 臨床放射學雜志, 2016, 35(4): 518-522.
3. 丘敏敏. 放療中T形口腔固定器的應用及食管癌肺受量預測模型的研究. 廣州: 南方醫科大學, 2021.
4. 牟文軒, 江慶華. 鼻咽癌患者經濟毒性研究進展. 廣西醫學, 2022, 44(6): 657-661.
5. Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force. Value Health, 2022, 25(1): 10-31.
6. 洪明晃, 麥海強, 羅東華. N_(2-3)鼻咽癌患者輔助化療的成本效果分析. 中國腫瘤, 2000, (12): 21-22.
7. 王仁生, 韋波, 蘇莉, 等. 鼻咽癌兩種放射治療方案的成本效果分析. 中華腫瘤防治雜志, 2011, 18(9): 707-709.
8. 區通源, 潘智靈. 鼻咽癌藥物療法的藥效分析. 西北藥學雜志, 2013, 28(1): 82-84.
9. 鄧勛, 劉海燕, 王艷, 等. 康艾注射液輔助治療鼻咽癌的臨床用藥評價. 實用藥物與臨床, 2014, 17(5): 547-550.
10. 楊珍珍. 甘氨雙唑鈉用于食管癌和鼻咽癌放療增敏的Meta分析及藥物經濟學評價. 石家莊: 河北醫科大學, 2019.
11. 劉友平, 呂星, 鄒雄, 等. 單純微創手術與調強放射治療原發性Ⅰ期鼻咽癌的療效比較. 癌癥, 2020, 39(5): 201-212.
12. 彭迎春. GP與DP治療晚期轉移性鼻咽癌療效及成本效果分析. 吉首: 吉首大學, 2020.
13. 邱英鵬, 孫潭霖, 趙羽西, 等. 螺旋斷層放射治療系統的成本效果分析. 中國醫學裝備, 2020, 17(12): 1-4.
14. 歐陽麗輝, 張順芝, 何鴿飛, 等. 吉西他濱或氟尿嘧啶聯合順鉑治療晚期鼻咽癌的藥物經濟學評價. 醫藥導報, 2021, 40(2): 257-262.
15. 陳夢宇, 文衛平, 李健, 等. 內鏡手術治療復發性rT1-rT3期鼻咽癌基于馬爾可夫模型的成本-效果分析. 中華耳鼻咽喉頭頸外科雜志, 2022, 57(11): 1304-1310.
16. Chen X, Liang W, Wan N, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol, 2019, 94: 80-85.
17. Liao W, Huang J, Wu Q, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: a cost-effectiveness analysis. Oral Oncol, 2019, 93: 15-20.
18. Fei Z, Xu T, Li M, et al. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol, 2020, 15(1): 230.
19. Jin C, Zheng H, Zhan M, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol, 2020, 277(2): 577-584.
20. Wu Q, Liao W, Huang J, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma. Oral Oncol, 2020, 103: 104588.
21. Yang J, Han J, He J, et al. Real-world cost-effectiveness analysis of gemcitabine and cisplatin compared to docetaxel and cisplatin plus fluorouracil induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol, 2020, 10: 594756.
22. She L, Tian K, Han J, et al. Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol, 2022, 12: 904372.
23. Tian K, Han J, Wang Z, et al. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis. Oral Oncol, 2022, 128: 105842.
24. Zhu Y, Liu K, Ding D, et al. Chemo-immunotherapy regimes for recurrent or metastatic nasopharyngeal carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol, 2022, 13: 858207.
25. Li G, Xia YF, Huang YX, et al. Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: cost-effectiveness analysis. Head Neck, 2022, 44(2): 431-442.
26. 中國臨床腫瘤學會指南工作委員會. 鼻咽癌診療指南2022. 北京:人民衛生出版社, 2022, 27: 47, 63, 69.
27. 何朝光, 傅萬凱, 陳彩霞, 等. 1990和2017年中國鼻咽癌疾病負擔及其趨勢. 海峽預防醫學雜志, 2020, 26(4): 108-110.
28. 王木清, 江文霞, 張靜. 鼻咽癌門診病例的臨床特征及健康教育. 中國醫藥指南, 2015, 13(4): 17-19.
29. 黃志碧. 廣西惡性腫瘤經濟負擔的現狀、變動的趨勢及其影響因素的研究. 南寧: 廣西醫科大學, 2016.

Previous Article
Economic evaluation of anti-novel coronavirus infection drugs: a systematic review
Next Article
Quality evaluation of pharmacoeconomics studies on Chinese patent medicines in neoplasm

Chinese Journal of Evidence-Based Medicine

Health economic evaluation in nasopharyngeal carcinoma: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content